Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSING AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN OPHTHOTECH CORPORATION AND NOVARTIS PHARMA AG MAY 19, 2014Licensing and Commercialization Agreement • August 6th, 2014 • Ophthotech Corp. • Pharmaceutical preparations • New York
This Licensing and Commercialization Agreement (“Agreement”) is made and effective as of the 19th day of May, 2014 (the “Effective Date”) by and between Ophthotech Corporation, a Delaware corporation, with offices at One Penn Plaza, 19th Floor, New York, NY 10119, U.S.A. (“Ophthotech”) and Novartis Pharma AG, a Swiss company, with offices at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”).
DATED THIS DAY OF 2014Licensing and Commercialization Agreement • July 18th, 2019 • Sabah
UNIVERSITI MALAYSIA SABAH, a public university established under the Universities and University Colleges Act 1971) with its principal office at Jalan UMS, 88400 Kota Kinabalu, Sabah (hereinafter referred to as “UMS”), of the one part;
LICENSING AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN SPARK THERAPEUTICS, INC. AND NOVARTIS PHARMA AG January 24, 2018Licensing and Commercialization Agreement • February 27th, 2018 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Licensing and Commercialization Agreement (“Agreement”) is entered into as of January 24, 2018 (the “Effective Date”) by and between Spark Therapeutics, Inc., a Delaware corporation, with offices at 3737 Market Street, Suite 1300, Philadelphia, PA 19104, USA (“Spark”) and Novartis Pharma AG, a Swiss company, with offices at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”).
